Apheresis as Therapy
Aferetica is an Innovative Small and Medium-sized Enterprise (SME), founded by Managers with tens of years of experience in Dialysis, Intensive Care, Cardiology and Medical Devices.
The company proposes itself as a catalyst for the creation of a Network of Clinicians, Academics, Researchers and Institutions, to create and validate New Apheretic Therapies, even for unexplored clinical areas.
An integrated and innovative vision of apheretic therapies is the challenge to face for a real evolution of the cure.
APHERESIS
Contribute to research for the development, creation and diffusion of complete apheretic therapies.
TRANSPLANTATION
For a concrete breakthrough in organ availability and transplantation outcome.
CRITICAL CARE
Apheresis as therapy: new frontiers in critically ill patients.
Our Therapeutic Systems
Products, knowledges, therapeutic protocols and clinical research.
Last updates
Second update on the possible use of CytoSorb in patients affected by COVID-19
Second update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe COVID-19 infection
Update on the possible use of CytoSorb in patients affected by COVID-19
We consider important to share an update on the news related to the possible use of CytoSorb as an adjuvant therapy against some complications in patients with severe infection with COVID-19
Possible use of CytoSorb in patients affected by COVID-19
In the recent days, we have witnessed the multiplication of cases of Covid-19 infection in Italy and Worldwide. Although this event should not be dramatized, we know that a percentage of these patients might present [...]